ArticleBlood cancer journal2022

Clinical outcomes in patients with relapsed/refractory FLT3-mutated acute myeloid leukemia treated with gilteritinib who received prior midostaurin or sorafenib.

Alexander E Perl et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.